Revive Adrenaline Auto-injector: Industrial Research

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show:

1. People do not carry them nearly as much as they should
2. Not receiving adrenaline for an anaphylactic reaction is the biggest common factor in fatalities as adrenaline is the only drug known to prevent death due to anaphylaxis
3. Women are a key area of concern as current needle lengths do not guarantee intramuscular delivery in this patient population

Revive is a new AAI concept developed as a graduation project at the _Royal College of Art (RCA)_. After successful technical feasibility of the Revive auto-injector in the Innovate UK Smart Grant January 2020 we can undertake activities for experimental evaluation at laboratory scale, evaluate proof of concept and safety, and explore potential production mechanisms in this proposed project. This project proposal is to validate the preliminary adherence to the regulatory requirements of an AAI and particular attention will be paid towards the supply chain (proof of concept aseptic filling and stoppering for container closure integrity in a lab-scale model). We will also conduct a user study to quantify comparative increase of our device being carried vs. existing products.

Designed with the patient at its centre, its credit card size makes it easy to carry and its form makes it discreetly fit within a patient's life. These combine like never before to counteract the identified problems of being too large to practically carry continuously. Revive, unlike most current offerings in the market, incorporates the UK Resuscitation Council's recommended guidelines for a longer needle to reduce the gender disparity in allergy management systems. Revive achieves this through a fresh examination of how a syringe should be designed for an AAI. The proprietary needle injection system concept has been awarded InnovationRCA's support and is patent pending in the UK (Intellectual property office has moved application towards grant).

The company is currently incubated at InnovationRCA, Medcity's Pilot Community Program and part of NHS Innovation Service Beta program. It has received publicity from _The Evening Standard_ & _Blueprint magazine_ and also won support from the Global Grad Show, British Invention Show and Embryo Ventures.